ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines

Initial $80m Series B From October Increased To $200m

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.

Genetic background with DNA strand. DNA spirals on a blue background.
ReCode also will expand its LNP delivery of genetic medicines to organs beyond the lungs • Source: Shutterstock

ReCode Therapeutics continues to evolve and expand its strategy for delivering genetic medicines with its novel selective organ targeting (SORT) lipid nanoparticle (LNP) technology, enabled by its latest financing, a $120m extension of its series B venture capital round that brings the total to $200m. The company plans to broaden the types of payloads its SORT LNPs can deliver and expand its pipeline beyond its two lead programs, which will begin clinical trials in 2023.

Menlo Park, CA-based ReCode merged with TranscripTx and raised an $80m series A round in March 2020 to develop RNA...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.